Therapeutic Peptide APIs Industry Research Report 2025

Summary

According to APO Research, the global Therapeutic Peptide APIs market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Therapeutic Peptide APIs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Therapeutic Peptide APIs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Therapeutic Peptide APIs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Therapeutic Peptide APIs include AmbioPharm, Aspen API, Bachem, Bio Basic, CordenPharma, CPC Scientific, GenScript, JPT Peptide Technologies and Limitless Biotech, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Therapeutic Peptide APIs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Therapeutic Peptide APIs.

The report will help the Therapeutic Peptide APIs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

The Therapeutic Peptide APIs market size, estimations, and forecasts are provided in terms of sales volume (Tons) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Therapeutic Peptide APIs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Therapeutic Peptide APIs Segment by Company

AmbioPharm
Aspen API
Bachem
Bio Basic
CordenPharma
CPC Scientific
GenScript
JPT Peptide Technologies
Limitless Biotech
Lonza
Piramal Pharma
PolyPeptide
ScinoPharm
Syngene
USV Peptides
Hybio Pharmaceutical
Guangdong Jianyuan Pharmaceutical
Jiangsu Sinopep-Allsino Biopharmaceutical
Zhejiang Peptites Biotech
Cheng Du Sheng Nuo Biotec
Hainan Shuangcheng Pharmaceuticals
Therapeutic Peptide APIs Segment by Type

Bioactive Peptides
Synthetic Peptides
Therapeutic Peptide APIs Segment by Application

Pharmaceuticals
Scientific Research
Other
Therapeutic Peptide APIs Segment by Region

North America

United States
Canada
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Therapeutic Peptide APIs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Therapeutic Peptide APIs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Therapeutic Peptide APIs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Therapeutic Peptide APIs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Therapeutic Peptide APIs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Therapeutic Peptide APIs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Therapeutic Peptide APIs Market Size (2020-2031)
2.2.2 Global Therapeutic Peptide APIs Sales (2020-2031)
2.2.3 Global Therapeutic Peptide APIs Market Average Price (2020-2031)
2.3 Therapeutic Peptide APIs by Type
2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
2.3.2 Bioactive Peptides
2.3.3 Synthetic Peptides
2.4 Therapeutic Peptide APIs by Application
2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.4.2 Pharmaceuticals
2.4.3 Scientific Research
2.4.4 Other
3 Market Competitive Landscape by Manufacturers
3.1 Global Therapeutic Peptide APIs Market Competitive Situation by Manufacturers (2020 Versus 2024)
3.2 Global Therapeutic Peptide APIs Sales (Tons) of Manufacturers (2020-2025)
3.3 Global Therapeutic Peptide APIs Revenue of Manufacturers (2020-2025)
3.4 Global Therapeutic Peptide APIs Average Price by Manufacturers (2020-2025)
3.5 Global Therapeutic Peptide APIs Industry Ranking, 2023 VS 2024 VS 2025
3.6 Global Manufacturers of Therapeutic Peptide APIs, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Therapeutic Peptide APIs, Product Type & Application
3.8 Global Manufacturers of Therapeutic Peptide APIs, Established Date
3.9 Global Therapeutic Peptide APIs Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
4.1 AmbioPharm
4.1.1 AmbioPharm Company Information
4.1.2 AmbioPharm Business Overview
4.1.3 AmbioPharm Therapeutic Peptide APIs Sales, Revenue and Gross Margin (2020-2025)
4.1.4 AmbioPharm Therapeutic Peptide APIs Product Portfolio
4.1.5 AmbioPharm Recent Developments
4.2 Aspen API
4.2.1 Aspen API Company Information
4.2.2 Aspen API Business Overview
4.2.3 Aspen API Therapeutic Peptide APIs Sales, Revenue and Gross Margin (2020-2025)
4.2.4 Aspen API Therapeutic Peptide APIs Product Portfolio
4.2.5 Aspen API Recent Developments
4.3 Bachem
4.3.1 Bachem Company Information
4.3.2 Bachem Business Overview
4.3.3 Bachem Therapeutic Peptide APIs Sales, Revenue and Gross Margin (2020-2025)
4.3.4 Bachem Therapeutic Peptide APIs Product Portfolio
4.3.5 Bachem Recent Developments
4.4 Bio Basic
4.4.1 Bio Basic Company Information
4.4.2 Bio Basic Business Overview
4.4.3 Bio Basic Therapeutic Peptide APIs Sales, Revenue and Gross Margin (2020-2025)
4.4.4 Bio Basic Therapeutic Peptide APIs Product Portfolio
4.4.5 Bio Basic Recent Developments
4.5 CordenPharma
4.5.1 CordenPharma Company Information
4.5.2 CordenPharma Business Overview
4.5.3 CordenPharma Therapeutic Peptide APIs Sales, Revenue and Gross Margin (2020-2025)
4.5.4 CordenPharma Therapeutic Peptide APIs Product Portfolio
4.5.5 CordenPharma Recent Developments
4.6 CPC Scientific
4.6.1 CPC Scientific Company Information
4.6.2 CPC Scientific Business Overview
4.6.3 CPC Scientific Therapeutic Peptide APIs Sales, Revenue and Gross Margin (2020-2025)
4.6.4 CPC Scientific Therapeutic Peptide APIs Product Portfolio
4.6.5 CPC Scientific Recent Developments
4.7 GenScript
4.7.1 GenScript Company Information
4.7.2 GenScript Business Overview
4.7.3 GenScript Therapeutic Peptide APIs Sales, Revenue and Gross Margin (2020-2025)
4.7.4 GenScript Therapeutic Peptide APIs Product Portfolio
4.7.5 GenScript Recent Developments
4.8 JPT Peptide Technologies
4.8.1 JPT Peptide Technologies Company Information
4.8.2 JPT Peptide Technologies Business Overview
4.8.3 JPT Peptide Technologies Therapeutic Peptide APIs Sales, Revenue and Gross Margin (2020-2025)
4.8.4 JPT Peptide Technologies Therapeutic Peptide APIs Product Portfolio
4.8.5 JPT Peptide Technologies Recent Developments
4.9 Limitless Biotech
4.9.1 Limitless Biotech Company Information
4.9.2 Limitless Biotech Business Overview
4.9.3 Limitless Biotech Therapeutic Peptide APIs Sales, Revenue and Gross Margin (2020-2025)
4.9.4 Limitless Biotech Therapeutic Peptide APIs Product Portfolio
4.9.5 Limitless Biotech Recent Developments
4.10 Lonza
4.10.1 Lonza Company Information
4.10.2 Lonza Business Overview
4.10.3 Lonza Therapeutic Peptide APIs Sales, Revenue and Gross Margin (2020-2025)
4.10.4 Lonza Therapeutic Peptide APIs Product Portfolio
4.10.5 Lonza Recent Developments
4.11 Piramal Pharma
4.11.1 Piramal Pharma Company Information
4.11.2 Piramal Pharma Business Overview
4.11.3 Piramal Pharma Therapeutic Peptide APIs Sales, Revenue and Gross Margin (2020-2025)
4.11.4 Piramal Pharma Therapeutic Peptide APIs Product Portfolio
4.11.5 Piramal Pharma Recent Developments
4.12 PolyPeptide
4.12.1 PolyPeptide Company Information
4.12.2 PolyPeptide Business Overview
4.12.3 PolyPeptide Therapeutic Peptide APIs Sales, Revenue and Gross Margin (2020-2025)
4.12.4 PolyPeptide Therapeutic Peptide APIs Product Portfolio
4.12.5 PolyPeptide Recent Developments
4.13 ScinoPharm
4.13.1 ScinoPharm Company Information
4.13.2 ScinoPharm Business Overview
4.13.3 ScinoPharm Therapeutic Peptide APIs Sales, Revenue and Gross Margin (2020-2025)
4.13.4 ScinoPharm Therapeutic Peptide APIs Product Portfolio
4.13.5 ScinoPharm Recent Developments
4.14 Syngene
4.14.1 Syngene Company Information
4.14.2 Syngene Business Overview
4.14.3 Syngene Therapeutic Peptide APIs Sales, Revenue and Gross Margin (2020-2025)
4.14.4 Syngene Therapeutic Peptide APIs Product Portfolio
4.14.5 Syngene Recent Developments
4.15 USV Peptides
4.15.1 USV Peptides Company Information
4.15.2 USV Peptides Business Overview
4.15.3 USV Peptides Therapeutic Peptide APIs Sales, Revenue and Gross Margin (2020-2025)
4.15.4 USV Peptides Therapeutic Peptide APIs Product Portfolio
4.15.5 USV Peptides Recent Developments
4.16 Hybio Pharmaceutical
4.16.1 Hybio Pharmaceutical Company Information
4.16.2 Hybio Pharmaceutical Business Overview
4.16.3 Hybio Pharmaceutical Therapeutic Peptide APIs Sales, Revenue and Gross Margin (2020-2025)
4.16.4 Hybio Pharmaceutical Therapeutic Peptide APIs Product Portfolio
4.16.5 Hybio Pharmaceutical Recent Developments
4.17 Guangdong Jianyuan Pharmaceutical
4.17.1 Guangdong Jianyuan Pharmaceutical Company Information
4.17.2 Guangdong Jianyuan Pharmaceutical Business Overview
4.17.3 Guangdong Jianyuan Pharmaceutical Therapeutic Peptide APIs Sales, Revenue and Gross Margin (2020-2025)
4.17.4 Guangdong Jianyuan Pharmaceutical Therapeutic Peptide APIs Product Portfolio
4.17.5 Guangdong Jianyuan Pharmaceutical Recent Developments
4.18 Jiangsu Sinopep-Allsino Biopharmaceutical
4.18.1 Jiangsu Sinopep-Allsino Biopharmaceutical Company Information
4.18.2 Jiangsu Sinopep-Allsino Biopharmaceutical Business Overview
4.18.3 Jiangsu Sinopep-Allsino Biopharmaceutical Therapeutic Peptide APIs Sales, Revenue and Gross Margin (2020-2025)
4.18.4 Jiangsu Sinopep-Allsino Biopharmaceutical Therapeutic Peptide APIs Product Portfolio
4.18.5 Jiangsu Sinopep-Allsino Biopharmaceutical Recent Developments
4.19 Zhejiang Peptites Biotech
4.19.1 Zhejiang Peptites Biotech Company Information
4.19.2 Zhejiang Peptites Biotech Business Overview
4.19.3 Zhejiang Peptites Biotech Therapeutic Peptide APIs Sales, Revenue and Gross Margin (2020-2025)
4.19.4 Zhejiang Peptites Biotech Therapeutic Peptide APIs Product Portfolio
4.19.5 Zhejiang Peptites Biotech Recent Developments
4.20 Cheng Du Sheng Nuo Biotec
4.20.1 Cheng Du Sheng Nuo Biotec Company Information
4.20.2 Cheng Du Sheng Nuo Biotec Business Overview
4.20.3 Cheng Du Sheng Nuo Biotec Therapeutic Peptide APIs Sales, Revenue and Gross Margin (2020-2025)
4.20.4 Cheng Du Sheng Nuo Biotec Therapeutic Peptide APIs Product Portfolio
4.20.5 Cheng Du Sheng Nuo Biotec Recent Developments
4.21 Hainan Shuangcheng Pharmaceuticals
4.21.1 Hainan Shuangcheng Pharmaceuticals Company Information
4.21.2 Hainan Shuangcheng Pharmaceuticals Business Overview
4.21.3 Hainan Shuangcheng Pharmaceuticals Therapeutic Peptide APIs Sales, Revenue and Gross Margin (2020-2025)
4.21.4 Hainan Shuangcheng Pharmaceuticals Therapeutic Peptide APIs Product Portfolio
4.21.5 Hainan Shuangcheng Pharmaceuticals Recent Developments
5 Global Therapeutic Peptide APIs Market Scenario by Region
5.1 Global Therapeutic Peptide APIs Market Size by Region: 2020 VS 2024 VS 2031
5.2 Global Therapeutic Peptide APIs Sales by Region: 2020-2031
5.2.1 Global Therapeutic Peptide APIs Sales by Region: 2020-2025
5.2.2 Global Therapeutic Peptide APIs Sales by Region: 2026-2031
5.3 Global Therapeutic Peptide APIs Revenue by Region: 2020-2031
5.3.1 Global Therapeutic Peptide APIs Revenue by Region: 2020-2025
5.3.2 Global Therapeutic Peptide APIs Revenue by Region: 2026-2031
5.4 North America Therapeutic Peptide APIs Market Facts & Figures by Country
5.4.1 North America Therapeutic Peptide APIs Market Size by Country: 2020 VS 2024 VS 2031
5.4.2 North America Therapeutic Peptide APIs Sales by Country (2020-2031)
5.4.3 North America Therapeutic Peptide APIs Revenue by Country (2020-2031)
5.4.4 United States
5.4.5 Canada
5.5 Europe Therapeutic Peptide APIs Market Facts & Figures by Country
5.5.1 Europe Therapeutic Peptide APIs Market Size by Country: 2020 VS 2024 VS 2031
5.5.2 Europe Therapeutic Peptide APIs Sales by Country (2020-2031)
5.5.3 Europe Therapeutic Peptide APIs Revenue by Country (2020-2031)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Russia
5.5.9 Spain
5.5.10 Netherlands
5.5.11 Switzerland
5.5.12 Sweden
5.5.13 Poland
5.6 Asia Pacific Therapeutic Peptide APIs Market Facts & Figures by Country
5.6.1 Asia Pacific Therapeutic Peptide APIs Market Size by Country: 2020 VS 2024 VS 2031
5.6.2 Asia Pacific Therapeutic Peptide APIs Sales by Country (2020-2031)
5.6.3 Asia Pacific Therapeutic Peptide APIs Revenue by Country (2020-2031)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 Taiwan
5.6.10 Southeast Asia
5.7 South America Therapeutic Peptide APIs Market Facts & Figures by Country
5.7.1 South America Therapeutic Peptide APIs Market Size by Country: 2020 VS 2024 VS 2031
5.7.2 South America Therapeutic Peptide APIs Sales by Country (2020-2031)
5.7.3 South America Therapeutic Peptide APIs Revenue by Country (2020-2031)
5.7.4 Brazil
5.7.5 Argentina
5.7.6 Chile
5.8 Middle East and Africa Therapeutic Peptide APIs Market Facts & Figures by Country
5.8.1 Middle East and Africa Therapeutic Peptide APIs Market Size by Country: 2020 VS 2024 VS 2031
5.8.2 Middle East and Africa Therapeutic Peptide APIs Sales by Country (2020-2031)
5.8.3 Middle East and Africa Therapeutic Peptide APIs Revenue by Country (2020-2031)
5.8.4 Egypt
5.8.5 South Africa
5.8.6 Israel
5.8.7 Türkiye
5.8.8 GCC Countries
6 Segment by Type
6.1 Global Therapeutic Peptide APIs Sales by Type (2020-2031)
6.1.1 Global Therapeutic Peptide APIs Sales by Type (2020-2031) & (Tons)
6.1.2 Global Therapeutic Peptide APIs Sales Market Share by Type (2020-2031)
6.2 Global Therapeutic Peptide APIs Revenue by Type (2020-2031)
6.2.1 Global Therapeutic Peptide APIs Sales by Type (2020-2031) & (US$ Million)
6.2.2 Global Therapeutic Peptide APIs Revenue Market Share by Type (2020-2031)
6.3 Global Therapeutic Peptide APIs Price by Type (2020-2031)
7 Segment by Application
7.1 Global Therapeutic Peptide APIs Sales by Application (2020-2031)
7.1.1 Global Therapeutic Peptide APIs Sales by Application (2020-2031) & (Tons)
7.1.2 Global Therapeutic Peptide APIs Sales Market Share by Application (2020-2031)
7.2 Global Therapeutic Peptide APIs Revenue by Application (2020-2031)
7.2.1 Global Therapeutic Peptide APIs Sales by Application (2020-2031) & (US$ Million)
7.2.2 Global Therapeutic Peptide APIs Revenue Market Share by Application (2020-2031)
7.3 Global Therapeutic Peptide APIs Price by Application (2020-2031)
8 Value Chain and Sales Channels Analysis of the Market
8.1 Therapeutic Peptide APIs Value Chain Analysis
8.1.1 Therapeutic Peptide APIs Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Therapeutic Peptide APIs Production Mode & Process
8.2 Therapeutic Peptide APIs Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Therapeutic Peptide APIs Distributors
8.2.3 Therapeutic Peptide APIs Customers
9 Global Therapeutic Peptide APIs Analyzing Market Dynamics
9.1 Therapeutic Peptide APIs Industry Trends
9.2 Therapeutic Peptide APIs Industry Drivers
9.3 Therapeutic Peptide APIs Industry Opportunities and Challenges
9.4 Therapeutic Peptide APIs Industry Restraints
10 Report Conclusion
11 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings